Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 396

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 396
---
 A Preferred Stock, Series A Common Warrants and Preferred Warrants, at a
price of $ per share of Series A Preferred Stock, for aggregate cash proceeds of approximately $ million, plus additional cash proceeds
of up to $ million if the Preferred Warrants are exercised.

The following table summarizes
the shares of our Series A Preferred Stock issued to our related parties:

| Purchasers                              |     | Shares             
 of                 
 Series A Preferred 
 Stock              |       |     | Total    
 Purchase 
 Price    |           |
|:----------------------------------------|:----|:-------------------|------:|:----|:---------|----------:|
| Daniel Corey(1)                         |     |                    |   150 |     | $        |   150,000 |
| Atwood-Edminster Trust dtd 4-2-2000 (2) |     |                    | 1,002 |     | $        | 1,002,000 |
| Chris Ehrlich(3)                        |     |                    |   275 |     | $        |   275,000 |

| (1) | Daniel Corey served as the Chief Technology Officer and a member of the board of directors of the Company from February 2024 to September 2024, and previously served as Chief Executive Officer, Chief Scientific Officer, and a member of the board of directors of Legacy CERo until the closing of the Business Combination in February 2024. |

| (2) | Brian G. Atwood served as Chairman and Chief Executive Officer of the Company from February 2024 to September 2024, and previously served as Chairman of PBAX until the closing of the Business Combination in February 2024. Mr. Atwood is currently a member of the board of directors of the Company and serves as a trustee of Atwood-Edminster Trust dtd 4-2-2000. |

| (3) | Chris Ehrlich has served as the Chairman and Chief Executive Officer of the Company since December 2024, and previously served as (i) interim Chairman and Chief Executive Officer of the Company from October 2024 to November 2024, (ii) Vice Chairman of the board of directors of the Company from February 2024 to September 2024, and (iii) the Chief Executive Officer of PBAX until the closing of the Business Combination in February 2024. |

NOTE 15 – SUBSEQUENT EVENTS On January 6, 2025,